The FDA has accepted Regeneron Pharmaceuticals’ sBLA for Eylea HD (aflibercept) injection 8mg for priority review.

Vision Australia is well on the way to reaching its annual target in the 100K Your Way fundraising challenge. For a second year, Vision Australia Radio ...

BRIDGEWATER, N.J. and BENGALURU, Karnataka, India, April 15, 2025 /PRNewswire/ -- Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon ...

Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), announced today a settlement and license agreement with ...

High cholesterol is a common health condition that doesn't usually produce any noticeable symptoms, but there are some ...

A new study found that an artificial intelligence reading label system improves ophthalmologists' diagnostic accuracy for retinal diseases and could be valuable in future medical education. A new ...

31,181 people played the daily Crossword recently. Can you solve it faster than others?31,181 people played the daily Crossword recently. Can you solve it faster than others?

for the treatment of patients with macular edema following retinal vein occlusion (RVO) including central, branch and hemiretinal vein occlusion. This would be the third indication for aflibercept 8 ...

2 Previous reporting from the QUASAR trial 3 indicated aflibercept 8 mg results were consistent across patients with branch RVOs, and those patients with central retinal or hemiretinal vein occlusions ...

Using synthetic data generated via conditioning with disease labels can enhance the pretraining efficiency and generalization of medical foundation models, as shown for the detection of eye ...

Aim: To describe the prevalence and risk factors of retinal vein occlusion (RVO) in an Asian population ... clinical examinations and laboratory investigations. RVO (central or branch) was graded ...